Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSILVA, Elaine C. da
dc.contributor.authorMACHADO, Darlene L.
dc.contributor.authorRESENDE, Maria B. D.
dc.contributor.authorSILVA, Renata F.
dc.contributor.authorZANOTELI, Edmar
dc.contributor.authorREED, Umbertina C.
dc.date.accessioned2013-07-30T15:08:21Z
dc.date.available2013-07-30T15:08:21Z
dc.date.issued2012
dc.description.abstractObjective: To assess the evolution of motor function in patients with Duchenne muscular dystrophy (DMD) treated with steroids (prednisolone or deflazacort) through the Motor Function Measure (MFM), which evaluates three dimensions of motor performance (D1, D2, D3). Methods: Thirty-three patients with DMD (22 ambulant, 6 non-ambulant and 5 who lost the capacity to walk during the period of the study) were assessed using the MFM scale six times over a period of 18 months. Results: All the motor functions remained stable for 14 months in all patients, except D1 for those who lost their walking ability. In ambulant patients, D2 (axial and proximal motor capacities) motor functions improved during six months; an improvement in D3 (distal motor capacity) was noted during the total follow-up. D1 (standing posture and transfers) and total score were useful to predict the loss of the ability to walk. Conclusions: The use of the MFM in DMD patients confirms the benefits of the steroid treatment for slowing the progression of the disease.
dc.description.abstractOBJETIVO: Avaliar a evolução da função motora de pacientes com distrofia muscular de Duchenne (DMD) em corticoterapia (predinisolona e deflazacort), por meio da escala Medida da Função Motora (MFM), que avalia três dimensões de funções motoras (D1, D2, D3). MÉTODOS: Trinta e três pacientes com DMD (22 deambulantes, seis cadeirantes e cinco que perderam a capacidade de andar ao longo do estudo) foram avaliados pela escala MFM em seis momentos durante 18 meses. RESULTADOS: Todas as funções motoras mantiveram-se estáveis durante 14 meses, exceto D1 para os pacientes que perderam a marcha. Nos pacientes deambulantes, a D2 (função motora axial e proximal) apresentou melhora durante seis meses. Melhora em D3 (função motora distal) também foi observada durante o seguimento. A D1 (postura em pé e transferências) e o escore total foram importantes para predizer a perda de marcha. CONCLUSÕES: O uso da MFM nos pacientes com DMD confirma os benefícios do tratamento com corticoides na diminuição da velocidade de progressão da doença.
dc.description.indexMEDLINE
dc.identifier.citationARQUIVOS DE NEURO-PSIQUIATRIA, v.70, n.3, p.191-195, 2012
dc.identifier.doi10.1590/S0004-282X2012000300007
dc.identifier.issn0004-282X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/776
dc.language.isoeng
dc.publisherASSOC ARQUIVOS NEURO- PSIQUIATRIA
dc.relation.ispartofArquivos de Neuro-Psiquiatria
dc.rightsopenAccess
dc.rights.holderCopyright ASSOC ARQUIVOS NEURO- PSIQUIATRIA
dc.subjectmotor function measure
dc.subjectmuscular dystrophy
dc.subjectDuchenne
dc.subjectneuromuscular disease
dc.subjectmedida da função motora
dc.subjectdistrofia muscular de Duchenne
dc.subjectdoença neuromuscular
dc.subject.othercorticosteroid treatment
dc.subject.otherneuromuscular diseases
dc.subject.othernatural-history
dc.subject.otherstrength
dc.subject.othermanagement
dc.subject.otherchildren
dc.subject.otherboys
dc.subject.wosNeurosciences
dc.subject.wosPsychiatry
dc.titleMotor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy
dc.title.alternativeMedida de função motora, corticoterapia e pacientes com distrofia muscular de Duchenne
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalSILVA, Renata F.:Univ Sao Paulo, Sch Med, Dept Neurol, Sao Paulo, Brazil
hcfmusp.author.externalZANOTELI, Edmar:Assoc Assistencia Crianca Deficiente, Neuromuscular Sect, Sao Paulo, Brazil
hcfmusp.citation.scopus13
hcfmusp.contributor.author-fmusphcELAINE CRISTINA DA SILVA
hcfmusp.contributor.author-fmusphcDARLENE LESSA MACHADO
hcfmusp.contributor.author-fmusphcMARIA BERNADETE DUTRA DE RESENDE
hcfmusp.contributor.author-fmusphcUMBERTINA CONTI REED
hcfmusp.description.beginpage191
hcfmusp.description.endpage195
hcfmusp.description.issue3
hcfmusp.description.volume70
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed22392111
hcfmusp.origem.scieloSCIELO:S0004-282X2012000300007
hcfmusp.origem.scopus2-s2.0-84858130484
hcfmusp.origem.wosWOS:000301080300007
hcfmusp.publisher.citySAO PAULO SP
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referenceALLSOP KG, 1981, ARCH NEUROL-CHICAGO, V38, P406
hcfmusp.relation.referenceBalaban B, 2005, AM J PHYS MED REHAB, V84, P843, DOI 10.1097/01.phm.0000184156.98671.d0
hcfmusp.relation.referenceBenaim C, 2010, REV NEUROL-FRANCE, V166, P49, DOI 10.1016/j.neurol.2009.05.005
hcfmusp.relation.referenceBerard C, 2005, NEUROMUSCULAR DISORD, V15, P463, DOI 10.1016/j.nmd.2005.03.004
hcfmusp.relation.referenceBerard C, 2006, REV NEUROL-FRANCE, V162, P485
hcfmusp.relation.referenceBiggar WD, 2006, NEUROMUSCULAR DISORD, V16, P249, DOI 10.1016/j.nmd.2006.01.010
hcfmusp.relation.referenceBROOKE MH, 1983, MUSCLE NERVE, V6, P91, DOI 10.1002/mus.880060204
hcfmusp.relation.referenceBushby K, 2010, LANCET NEUROL, V9, P77, DOI 10.1016/S1474-4422(09)70271-6
hcfmusp.relation.referenceBushby K, 2004, Neuromuscul Disord, V14, P526, DOI 10.1016/j.nmd.2004.05.006
hcfmusp.relation.referenceBushby K, 2007, NEUROMUSCULAR DISORD, V17, P423, DOI 10.1016/j.nmd.2007.01.006
hcfmusp.relation.referenceConnolly AM, 2002, NEUROMUSCULAR DISORD, V12, P917, DOI 10.1016/S0960-8966(02)00180-3
hcfmusp.relation.referenceFENICHEL GM, 1991, NEUROLOGY, V41, P1874
hcfmusp.relation.referenceHoude S, 2008, PEDIATR NEUROL, V38, P200, DOI 10.1016/j.pediatrneurol.2007.11.001
hcfmusp.relation.referenceIwabe C, 2008, REV BRAS FISIOTER, V12, P417
hcfmusp.relation.referenceManzur AY, 2008, ARCH DIS CHILD, V93, P986, DOI 10.1136/adc.2007.118141
hcfmusp.relation.referenceMartinez Jose Antonio Baddini, 2006, Rev Assoc Med Bras, V52, P347
hcfmusp.relation.referenceMc Donald CM, 1995, AM J PHYS MED REH S, V74, P70
hcfmusp.relation.referenceMercuri E, 2008, Neuromuscul Disord, V18, P894, DOI 10.1016/j.nmd.2008.07.003
hcfmusp.relation.referenceMoxley RT, 2010, J CHILD NEUROL, V25, P1116, DOI 10.1177/0883073810371004
hcfmusp.relation.referenceNair KPS, 2001, J REHABIL MED, V33, P147, DOI 10.1080/165019701750300591
hcfmusp.relation.referenceParreira Samara Lamounier Santana, 2007, Arq Neuropsiquiatr, V65, P245
hcfmusp.relation.referenceParreira SLS, 2010, ARQ NEURO-PSIQUIAT, V68, P683, DOI 10.1590/S0004-282X2010000500002
hcfmusp.relation.referenceScott E, 2006, DEV MED CHILD NEUROL, V48, P540, DOI 10.1017/S0012162206001137
hcfmusp.relation.referenceSCOTT OM, 1982, MUSCLE NERVE, V5, P291, DOI 10.1002/mus.880050405
hcfmusp.relation.referenceSteffensen B, 2001, Physiother Res Int, V6, P119, DOI 10.1002/pri.221
hcfmusp.relation.referenceVuillerot C, 2010, DEV MED CHILD NEUROL, V52, P60, DOI 10.1111/j.1469-8749.2009.03316.x
hcfmusp.relation.referenceWagner KR, 2008, NEUROTHERAPEUTICS, V5, P583, DOI 10.1016/j.nurt.2008.08.013
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication5519f512-00a0-4eb2-8e33-7efce854e5ae
relation.isAuthorOfPublicationf074be7d-155a-47ae-a9bf-67b62498b991
relation.isAuthorOfPublication04aa580f-f021-4eaf-b438-5bd456408dd2
relation.isAuthorOfPublicationcc9aed67-4ca0-4cc5-80be-c3e5fa74f07a
relation.isAuthorOfPublication.latestForDiscovery5519f512-00a0-4eb2-8e33-7efce854e5ae
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
art_SILVA_Motor_function_measure_scale_steroid_therapy_and_patients_2012.PDF
Tamanho:
120.61 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)